of multiple chemotherapy agents.
The distribution of tumor infiltrating lymphocytes (TILs) could also predict responses to neoadjuvant [8] [9] [10] [11] [12] and adjuvant chemotherapies [13] [14] [15] in solid cancers. TIL distribution is an independent prognostic marker for gastric cancer and other solid cancers. 8, 10, 16, 17 Gastric medullary carcinomas that have extensive infiltration of lymphocytes often show excellent prognosis. 18 Thus, improving predictions for chemo-responsiveness is a highly desirable possibility when combining ATP-CRA results and TIL distribution. The aim of the present study was to explore the possibility of selecting patient-specific sensitive chemotherapeutic agents based on TIL-related immune microenvironments.
Materials and Methods
Patients
At Severance Hospital, Yonsei University College of Medi- 
Adenosine triphosphate-based-based chemotherapy response assays
ATP-CRAs were performed as previously described. 6 Briefly, a 0.5-cm 3 sample of cancer tissue was collected, stored in Hank's balanced salt solution (GIBCO BRL, Rockville, MD, USA) containing 100 IU/ml penicillin (Sigma, St. Louis, MO, USA), 100 mg/ml streptomycin (Sigma), 100 mg/ml gentamicin (GIBCO BRL), 2.5 mg/ml amphotericin B (GIBCO BRL), and 5% fetal bovine serum (GIBCO BRL), and immediately sent to the pathology laboratory. Tissues were washed, quantified, minced, and enzymatically dissociated. Cells were purified by density centrifugation to eliminate debris. After dilution of the separated tumor cells to 2×10 4 cells/ml, cells were seeded in triplicate in 96-well microplates (Costar, Cambridge, MA, USA).
In the treated groups, 100 ml of chemotherapeutic agents were added to the seeded cells, and 100 ml of Iscove's modified Dulbecco's medium (GIBCO BRL) without chemotherapeutic agents were added to the untreated control groups. Samples from each patient were individually treated with each of the chemotherapeutic agents. The test drug concentrations were determined based on peak plasma concentrations according to previous reports: etoposide (3.57 mg/ml), doxorubicin (1.5 mg/ml), epirubicin (1.2 mg/ml), mitomycin (0.2 mg/ml), 5-fluorouracil (5-FU, 10 mg/ml), oxaliplatin (2.9 mg/ ml), irinotecan (4.7 mg/ml), docetaxel (3.7 mg/ml), paclitaxel (8.5 mg/ml), methotrexate (0.37 mg/ml), and cisplatin (2.5 mg/ml).
19-21
Three different doses (0. 
Quantification of tumor infiltrating lymphocyte subsets
Immunohistochemical staining and quantification of TIL subsets was performed as previously described. 16 Paraffin- 
Statistical analysis
Pearson's correlation tests were performed for cancer cell death rates and TIL subsets. Absolute numbers of cells positive for each stain were dichotomized using cut-off values derived by the median. Survival curves were constructed using the Kaplan-Meier method, and the log-rank test was used to evaluate the significance. A statistical significance level was defined as a P-value of 0.05 or less. All statistical analyses were performed with SAS 9.2 software (SAS Institute, Cary, NC, USA).
Results

Clinicopathological characteristics
The clinicopathological features of 15 patients are presented in 
In vitro chemosensitivity test results
The cytotoxic effect of the chemotherapeutic agents tested at previously published peak plasma concentrations [19] [20] [21] ranged from 0% to 72.7% cell death ( Table 2 
Subsets of tumor infiltrating lymphocytes
The median number of cells positive for CD3, CD4, CD8, Foxp3, and Granzyme B were 156.0, 64.7, 80.7, 15.3, and 10, Values are presented as number (%) or mean only. *Classification according to the standard of American Joint Committee on Cancer, 7th edition.
respectively (Table 3) . Using the median values, all cases were classified into low-and high-density groups for each variable and survival rates were compared. A higher number of total T lymphocytes (CD3) was a good prognostic factor (P=0.008; Fig. 1C ). 
Association between cancer cell death rates and tumor infiltrating lymphocyte subsets
Pearson's correlation tests showed no statistically significant association between cancer cell death rates as determined by ATP-CRA for each chemotherapeutic agent and the TIL subsets from the correlating patient (Table 4) (Fig. 2A~C) . The most commonly used chemotherapeutic agents in Korea, 5-FU and cisplatin, also showed no significant association with the CD3 subset, which showed prognostic implications in this study (Fig. 2D, E) .
Discussion
Accumulating evidence suggests that the immune microenvironment alters chemo-responsiveness. 22, 23 Previous studies on chemo-responsiveness used various chemotherapeutic agents for different types of cancer. Thus, translation of the results to gastric cancer treatment is challenging. For example, high posttreatment levels of CD3 or CD8 TIL subsets in the tumor microenvironment correlates with more robust responses to paclitaxel neoadjuvant chemotherapy in breast cancer. 24 Additionally, the density of CD8 TILs affects the chemo-responsiveness to 5-FU in stage III colon cancer. 25 Higher densities of CD3, CD8, and Granzyme B, but not of Foxp3 TILs at invasive margins are related to improved chemo-responsiveness to irinotecan-and platinum-based chemotherapies in metastatic colorectal cancer. 26 Furthermore, the level of regulatory T cells prior to chemotherapy is a predictive marker for early breast cancer. 27 However, the relationship of the immune microenvironment and chemoresponsiveness in gastric cancer has never been studied. To explore whether cancer cell response to chemotherapeutic agents has any relationship with immune microenvironments, we investigated the association of cancer cell death rates in ATPCRAs and the distribution of TIL subsets within the tumor tissue microenvironment. However, no significant associations were identified.
It is unknown whether TILs cause or enhance susceptibility to chemotherapeutic agents or are simply chemosensitiv- patients, emphasizing the need for further validation of these observations in additional data sets; only a small portion of the patients were treated according to ATP-CRA results; and the biological mechanism underlying these observations was not studied. Despite these limitations, we tried to assess the association of chemosensitivity test results and TIL subsets in gastric cancer. No significant association between the two suggests that current ATP-CRA has limitations for predicting cancer cell destruction, which could be affected by the immune system.
In conclusion, cancer cell death rates in response to specific chemotherapeutic agents had a poor association with the distribution of TIL subsets.
